Jones Paul W
Respiratory Medicine, St. George's Hospital Medical School, London SW 17 0RE, UK.
Proc Am Thorac Soc. 2004;1(3):167-70. doi: 10.1513/pats.200402-012MS.
Chronic obstructive pulmonary disease (COPD) has multiple pathophysiologic effects that are not confined to the lungs. Similarly, treatment for COPD may have a number of different beneficial effects, and although each of these may be small, their cumulative effect may add up to a worthwhile overall outcome. Many of the effects of COPD are only weakly related to FEV(1), and there is good evidence that health status questionnaires are the best overall measures of disease severity. Recently it has been shown, using such instruments, that health status in patients with COPD deteriorates progressively and at a measurable rate. Fluticasone reduces that decline, an effect that may take months to be detectable but continues to develop over 3 years. The effect of fluticasone on health appears to be due to a reduction in exacerbations coupled with its small effect on FEV(1).
慢性阻塞性肺疾病(COPD)具有多种病理生理效应,且并不局限于肺部。同样,COPD的治疗可能会产生许多不同的有益效果,尽管这些效果可能都很微小,但它们的累积效应可能会带来总体上有价值的结果。COPD的许多效应与第一秒用力呼气容积(FEV₁)仅有微弱关联,并且有充分证据表明,健康状况问卷是评估疾病严重程度的最佳整体指标。最近通过使用此类工具表明,COPD患者的健康状况会逐渐恶化,且恶化速度可测量。氟替卡松可减缓这种恶化,这种效果可能需要数月才能检测到,但会在3年多的时间里持续显现。氟替卡松对健康的影响似乎是由于加重发作次数减少以及其对FEV₁的微小作用。